• Latest Posts

ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies

Circassia Moves Away from a Failed Allergy Pipeline with Phase III Success

Circassia Freezes its Allergy Portfolio after a Second Failed Clinical Trial

Can this British Biotech Overcome Failure buying drugs from AstraZeneca?

The 8 Biggest Biotech Medical Fails of 2016 in Europe

ADVERTISEMENT